Special Issue "TGF-Beta Signaling in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2018)
Prof. Dr. Hendrik Ungefroren
University of Lübeck and First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), c/o Center of Brain, Behavior and Metabolism (CBBM) Ratzeburger Allee 160, 23538 Lübeck, Germany
Website | E-Mail
Interests: TGF- signaling and its crosstalk with other signaling pathways; cell migration and invasion; mechanisms of metastasis; tumor biology; stem cells
Transforming growth factor (TGF)-β plays pivotal roles in the control of different cellular processes, including proliferation, cell death, differentiation, and migration during both embryonic development and adulthood. Not surprisingly, dysregulation of its expression and/or altered activation of its intracellular signaling pathways contributes to human diseases, such as tissue fibrosis and cancer. During tumorigenesis, TGF-β may have anticancer activity at early stages, which is mainly due to its strong antiproliferative effect; however, strong evidence suggests that mutational inactivation of the canonical Smad pathway with concurrent overactivation of non-canonical Smad and non-Smad pathways could at later stages contribute to tumor progression by favoring immune suppression, cell invasion, and metastasis. Authors are invited to submit manuscripts that show how these pathways interact (crosstalk) with each other in tumor cells as compared to untransformed cells. The data may provide useful information on how to better and more selectively target TGF-β signaling for inhibition in various types of human cancer with the goal to enhance survival rates of cancer patients.
In this Special Issue, we aim to shed light on the state-of-the-art, as well as novel data, that contribute to increasing our knowledge on the role of TGF-β signaling in the development and progression of human cancer. We welcome experts in the field to contribute research papers and critical reviews on the various facets of TGF-β signaling that either suppress or promote cancer development, as well as on how natural and pharmacological pathway inhibitors for TGF-β signaling may be exploited as tools in anti-cancer therapies.
Prof. Dr. Hendrik Ungefroren
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- signaling crosstalk
- Smad signaling
- non-Smad signaling
- TGF-beta receptors
- TGF-beta signaling inhibitors
- TGF-beta paradox
- altered/mutated signaling pathways